EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zoetis's enterprise value is $73,249 Mil.
Zoetis's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $3,666 Mil. Therefore, Zoetis's EV-to-EBITDA for today is 19.98.
The historical rank and industry rank for Zoetis's EV-to-EBITDA or its related term are showing as below:
ZTS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.52 Med: 23.93 Max: 38.76
Current: 19.98
During the past 13 years, the highest EV-to-EBITDA of Zoetis was 38.76. The lowest was 16.52. And the median was 23.93.
ZTS's EV-to-EBITDA is ranked worse than 67.33% of 707
companies
in the Drug Manufacturers industry
Industry Median: 13.91
vs ZTS: 19.98
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-16), Zoetis's stock price is $149.77.
Zoetis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $5.070. Therefore, Zoetis's PE Ratio for today is 29.54.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Zoetis EV-to-EBITDA Historical Data
The historical data trend for Zoetis's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Zoetis Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBITDA
27.76
30.90
37.53
21.69
25.96
Zoetis Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
21.69
24.52
23.84
23.57
25.96
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis EV-to-EBITDA Distribution
For the Drug Manufacturers industry and Healthcare sector, Zoetis's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zoetis's EV-to-EBITDA falls into.
Zoetis's current Enterprise Value is $73,249 Mil.
Zoetis's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,666 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis (NYSE:ZTS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Zoetis's share price for today is $149.77.
Zoetis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Zoetis's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZTS has been successfully added to your 